
7oh intent to schedule released
Federal thresholds now target chemically manipulated products
━━━━━━━━━━━━━━━━━━━━━━━
Important news from Washington
━━━━━━━━━━━━━━━━━━━━━━━
The U.S. Department of Justice announced today that the DEA will issue a new Notice of Intent on 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl that adopts concentration thresholds recommended by Department of Health and Human Services (HHS).
"HHS recommended that 7-OH and MGPI be subject to Schedule I control when either substance alone, or their combined amount when both are present, exceeds 1 milligram per gram in solid products or 1 milligram per milliliter in liquid products, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1.
HHS recommended this approach to better distinguish products intentionally enhanced or concentrated in these opioid substances from products whose alkaloid composition is more consistent with botanical kratom."
In plain terms: federal enforcement will target chemically manipulated opioid products — not natural kratom leaf, which contains only trace amounts of these alkaloids.
This is the distinction the American Kratom Association has fought for, including through our litigation challenging the unintended consequences of the earlier scheduling action. AKA applauds the DEA and the Department of Justice for getting it right, and we are urging states to follow this science-based model rather than enact sweeping bans.
Read the details:
DOJ announcement